Immunogenicity of Peptide Medicines
Why the immune system sometimes makes antibodies against peptide medicines, how impurities and PEG add to the risk, what a semaglutide label reports, and why a test result is not a clinical verdict.
Content last updated . This page has not been medically reviewed.
Quick overview
Immunogenicity means the tendency of a medicine to provoke an immune response. For peptide drugs, the usual finding measured is anti-drug antibodies (ADAs): antibodies the body makes against the drug. ADAs may do nothing noticeable, may weaken the drug, or may be linked to side effects, depending on the product. This page is science education about how regulators and researchers think about it. It is not a reason to start, stop or change any medicine.Evidence labels used here: approved medicine where a US label is the source, and established for definitions from reviews.
Why it matters
A review on harmonizing immunogenicity terms says immunogenicity is a significant concern for biologic drugs because it can affect both safety and efficacy. [1] The same authors say that to judge clinical relevance one must look at ADA incidence, timing, size, neutralizing ability, cross-reaction with the body's own molecule, and links to drug levels, efficacy and safety. [1]Immunogenicity differs from product to product, so it has to be assessed for each one.
A label example: semaglutide
The US Ozempic label (Novo Nordisk, DailyMed version published 2026-06-10) reports that 32 of 3,150 treated patients (1%) in glycemic-control trials developed antibodies to semaglutide. Of those 32, 19 (0.6% of the overall population) had antibodies that cross-reacted with native GLP-1. [4] The label says the in vitro neutralizing activity is uncertain. [4] It also warns that the observed incidence depends heavily on assay sensitivity and specificity, so rates from different studies or products cannot be compared meaningfully. [4]That caution is the key lesson. An ADA percentage from one trial is not a risk score for another peptide or a different assay. It also does not state what, if anything, antibodies mean for an individual patient. See Semaglutide: Medicine Overview.
Reading immunogenicity claims
- "No antibody response" needs an assay description, a population and a time frame.
- A low ADA rate in one trial does not mean the same for a different product from a different maker.
- Antibodies on a lab test and symptoms are different findings. The review calls for linking ADA to pharmacokinetics, efficacy and safety. [1]
Frequently asked questions
What does anti-drug antibody mean?
An antibody the body makes against a medicine. Whether it matters depends on its size, timing and neutralizing ability. [1]
Are peptide medicines immunogenic?
They can be. The review says impurities in synthetic peptides can trigger immune responses. [2]
What did the semaglutide label report?
About 1% of trial patients developed antibodies, and the label calls their neutralizing activity uncertain. [4]
Can antibody rates be compared across products?
The label says assay differences prevent meaningful comparison. [4]
What should someone do if worried about an immune reaction to a medicine?
Contact the prescriber or pharmacist. This page cannot assess an individual case.
More details: evidence, limits and cautions
The details behind this page: cautions, limits of the evidence and where sources disagree. Open any note to read it.
What can raise the risk
- Impurities. A 2023 review states that impurities in synthetic peptide drugs can elicit unwanted immune responses by introducing T-cell epitopes (short fragments that immune cells recognize). [2] The same review notes that of 80 approved peptide drugs, at least five are off-patent and being developed as generics, and that the FDA's abbreviated pathway asks sponsors to describe new impurities compared with the original product. [2]
- PEG. A review of PEGylated therapeutics links PEG to anti-PEG antibodies and complement activation causing hypersensitivity reactions, while stressing that antibody claims are limited by the lack of standardized, validated assays. [3] It covers PEGylated therapeutics broadly, not peptides alone. See Lipidation, PEGylation and Cyclization.
- Product quality. Aggregation and degradation can alter what the immune system sees; the same concern appears in Stability and Storage: Why Peptides Degrade. No source I read measured this link for specific peptides, so it is a stated concern, not a quantified one.
Immunogenicity and unapproved products
References
- Assessment and reporting of the clinical immunogenicity of therapeutic proteins and peptides: harmonized terminology and tactical recommendations (2014). Read 2026-10-22.
- Immunogenicity risk assessment of synthetic peptide drugs and their impurities (2023). Read 2026-10-22.
- Potential induction of anti-PEG antibodies and complement activation toward PEGylated therapeutics (2014). Read 2026-10-22.
- OZEMPIC (semaglutide) injection, prescribing information, Novo Nordisk, DailyMed label published 2026-06-10. U.S. National Library of Medicine. Read 2026-10-22.